IDiyas

For the Inventor, By the Inventor

Xi'an, China

Chengyuan Liang

USPTO Granted Patents = 58 

Average Co-Inventor Count = 8.6

ph-index = 2

Forward Citations = 20(Granted Patents)

DiyaCoin DiyaCoin = 0.01 


Inventors with similar research interests:


Location History:

  • Xi+3 an, CN (2022 - 2023)
  • Xi'an, CN (2017 - 2024)

Company Filing History:

goldMedal43 out of 104 
 
Shaanxi University of Science and Technology
 patents
silverMedal6 out of 9 
 
Xi'an Taikomed Pharmaceutical Technology Co., Ltd.
 patents
bronzeMedal5 out of 5 
 
Shaanxi Panlong Pharmaceutical Co., Ltd.
 patents
4. 3 out of 4 
 
Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd.
 patents
5. 1 out of 1 
 
Xixian New District Fenghou Original Pharmaceutical Technology Co., Ltd.
 patent
6. 1 out of 3 
 
Xi'an Kangyuansheng Biomedical Technology Co., Ltd.
 patents
where one patent can have more than one assignee

Years Active: 2017-2025

where 'Filed Patents' based on already Granted Patents

58 patents (USPTO):
1. 12304917 - Pleuromutilin derivative containing a thiazolo[5,4-c]pyridine side chain, and a preparation method and application thereof (2025-05-20),
2. 12275734 - Pleuromutilin onium salt derivative containing a 3H-imidazo[4,5-c]pyridine side chain, and a preparation method and application thereof (2025-04-14),
3. 12221424 - 3-tetrazolylmethyl-1,3,5-triazin-2,4-dione compound inhibiting coronavirus 3CL protease activity and preparation method and use thereof (2025-02-11),
4. 12201665 - Polygoni Milletii Rhizome compositions and methods of preparing the same (2025-01-21),
5. 11872202 - Pleuromutilin cinnamic acid ester compounds with activities against antibiotic-resistant infections (2024-01-16),
6. 11712457 - seed extract composition and its application in antibiotic-resistant infections (2023-08-01),
7. 11639516 - Hydroxytyrosol sturgeon skin gelatin film with antioxidant activity anddetection ability and a method of preparing the same (2023-05-02),
8. 11612603 - 3-triazolyl methyl-1,3,5-triazine-2,4-dione compounds and preparation method and application thereof (2023-03-28),
9. 11597714 - Pleuromulin lipoic acid ester with antibacterial activity and a method of preparing the same (2023-03-07),
10. 11555016 - Pleuromulin 7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid ester with antibacterial activity and a method of preparing the same (2023-01-17),
11. 11530195 - Protacs targeting coronavirus 3CL protease and preparation method and application thereof (2022-12-20),
12. 11518759 - Protacs based on VHL ligand targeting coronavirus 3CL protease and preparation method and application thereof (2022-12-06),
13. 11518740 - Pleuromutilin (phenylthio)acetic acid ester with anti-drug resistant bacteria activity and a method of preparing the same (2022-12-06),
14. 11512049 - Pleuromutilin 2-[(diphenylmethyl)thio] acetic acid ester with anti-drug resistant bacteria activity and a method of preparing the same (2022-11-29),
15. 11510905 - Pleuromutilin (E)-4-(1-imidazoylmethyl)cinnamic acid ester with anti-drug resistant bacteria activity and a method of preparing the same (2022-11-29),

Title: Innovations of Chengyuan Liang in Medicinal Chemistry

Introduction

Chengyuan Liang, based in Xi'an, China, is a prominent inventor with an impressive portfolio of 56 patents. His work primarily focuses on the field of medicinal chemistry, where he has made significant strides toward developing innovative pharmaceutical compounds aimed at combating viral diseases.

Latest Patents

Among his latest contributions to the field, Chengyuan Liang has developed a notable patent for a 3-tetrazolylmethyl-1,3,5-triazin-2,4-dione compound that effectively inhibits coronavirus 3CL protease activity. This invention is particularly relevant as it addresses the pressing challenge posed by the SARS-CoV-2 virus. The method for preparing this compound not only aims to hinder the virus’s replication and transcription in patients but also demonstrates high in-vitro safety, showing promise for future anti-SARS-CoV-2 drug development.

Additionally, he has patented a method for preparing a tincture from Polygoni Milletii Rhizome. This method includes the extraction of the rhizome using ethanol and the creation of a poultice that combines various agents to enhance skin penetration. Both inventions reflect Liang's dedication to advancing drug formulation and therapeutic applications.

Career Highlights

Throughout his career, Chengyuan Liang has made his mark in the pharmaceutical industry through his association with esteemed institutions. He has worked at the Shaanxi University of Science and Technology, where he has likely influenced budding scientists and researchers. Additionally, he is affiliated with Xi'an Taikomed Pharmaceutical Technology Co., Ltd., contributing his expertise to pharmaceutical development projects.

Collaborations

Liang has collaborated with several notable individuals in the field, including his coworkers Han Li and Xingke Ju. His partnerships have enriched his work, combining diverse skills and perspectives to enhance the effectiveness of innovative approaches in medicinal chemistry.

Conclusion

Chengyuan Liang's contributions to the field of medicinal chemistry through his numerous patents demonstrate his innovative spirit and commitment to public health. His latest work, particularly in developing inhibitors against coronavirus activity, showcases the critical role inventors play in responding to global health challenges. As he continues to build on his impressive body of work, the pharmaceutical industry eagerly anticipates the impact of his future inventions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…